What happened with ODTX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Odyssey Therapeutics is a clinical-stage biotechnology company whose lead drug candidate, OD-001, is an oral medicine in a phase 2a trial for ulcerative colitis. Its next most advanced candidate, OD-002, is undergoing studies needed before human trials can begin. Both are wholly owned, and the company has no approved products.
Drug companies have paid Odyssey for joint research and access to its drug-discovery intellectual property. Most historical collaboration revenue came from Janssen Pharmaceutica NV, a Johnson & Johnson company, with Pfizer supplying the remainder. Odyssey has completed its current obligations to J&J, and the Pfizer agreement expired in 2025; it does not anticipate further revenue from either agreement.
Odyssey has funded operations mainly by selling shares, supplemented by collaboration and licensing proceeds, and needs additional capital to keep developing its medicines. Future drug sales depend on successful clinical development and regulatory approval: it cannot market a candidate without the applicable approval. It also relies on outside providers to run studies and manufacture drug supplies.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Odyssey’s prospects hinge chiefly on OD-001’s ulcerative colitis clinical results; watch Accro Bioscience and Oncodesign Precision Medicine for closer RIPK2 competitors absent from this list.
Kymera Therapeutics competes with Odyssey in oral medicines for immune diseases targeting IRF5 and IRAK4, but uses different mechanisms, including removing target proteins rather than blocking their activity. Its clinical-stage IRF5 drug KT-579 is worth watching alongside Odyssey’s partnered IRF5 inhibitor.
Takeda’s ENTYVIO already serves ulcerative colitis patients Odyssey hopes to treat with its investigational oral drug OD-001. ENTYVIO, also sold for Crohn’s disease, is Takeda’s top-selling medicine; its sales show the established treatment business OD-001 would enter.
Alumis’s IRF5 research competes with Odyssey’s partnered IRF5 program, rather than its lead drug OD-001. Both develop medicines for autoimmune disease; Alumis’s IRF5 research progress is the most direct overlap to watch, not sales of an approved product.
Nektar Therapeutics competes with Odyssey’s OD-003 by developing medicines intended to activate TNFR2 for autoimmune and inflammatory diseases. Progress in Nektar’s TNFR2 programs is the relevant comparison for OD-003’s approach, which aims to increase the number and function of immune-regulating T cells.
Nurix Therapeutics and Gilead’s clinical-stage drug removes IRAK4, competing with Odyssey’s preclinical approach of blocking IRAK4’s interactions with other proteins. Nurix earns revenue from drug-discovery partners rather than product sales; clinical results for GS-6791/NX-0479 are the direct comparison to watch for Odyssey’s inflammatory-disease program.
Attovia Therapeutics could compete with Odyssey’s immune-disease medicines through biologic drugs that act on multiple targets, including a program for inflammatory bowel disease.
Johnson & Johnson is both a rival and a customer for Odyssey: its inflammatory-bowel-disease medicines compete with OD-001, while Janssen paid Odyssey for drug-discovery services and the right to choose commercial licenses.
AstraZeneca’s tezepelumab and tozorakimab respiratory programs compete along the pathways Odyssey aims to block together with its TSLP/IL-33 bispecific medicine. Its IRAK4 research also overlaps Odyssey’s separate IRAK4 program.
Fed Interest Rate Decision
Odyssey’s U.S. Treasury holdings and money-market cash earn interest, so changes in rates can change the income it receives from those assets.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise the interest Odyssey earns as Treasury holdings mature and cash investments reset, adding income available to fund research and development.
If it comes in below expectations
Lower rates can reduce the interest Odyssey earns as Treasury holdings mature and cash investments reset, leaving less income available to fund research and development.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda's report will show how ENTYVIO, an established ulcerative-colitis treatment, is selling in the market Odyssey's OD-001 would enter.
Watch Takeda's reported ENTYVIO sales, bearing in mind that the medicine also treats Crohn's disease. Growth would show that demand for this established medicine remains strong across its uses, making it a substantial commercial competitor for OD-001; weaker sales would point to pressure on that business, but would not isolate ulcerative-colitis demand or prove whether OD-001 can succeed.
AstraZeneca PLC earningsAZN
Any updates in AstraZeneca's report on its respiratory programs or IRAK4 research will show how another company is advancing in areas that overlap with Odyssey's research.
Watch for disclosed progress or delays in AstraZeneca's tezepelumab and tozorakimab programs or its IRAK4 research. These overlap with pathways Odyssey is pursuing: progress would show another company advancing related approaches and could intensify competition, while delays would soften that signal but would not make Odyssey's programs more effective.
Kymera Therapeutics, Inc. earningsKYMR
If Kymera Therapeutics reports clinical progress for its IRF5 drug KT-579, readers can see how a competing program against the same target is advancing alongside Odyssey's partnered research.
Watch for clinical updates on KT-579, keeping its mechanism distinct from Odyssey's partnered IRF5 inhibitor: KT-579 removes the target protein rather than blocking its activity. Progress would show another approach to the same target advancing and make the competitive overlap more concrete; a delay would weaken that near-term signal, but would not establish whether Odyssey's inhibitor works.
Odyssey Therapeutics, Inc. earningsThis company
Odyssey Therapeutics' report will show whether its lead ulcerative-colitis drug, OD-001, is progressing through trials as the company uses cash to develop it.
Read any OD-001 trial update alongside research spending and cash and marketable securities. Continued progress with cash use still manageable against the company's funding plan would show that available funds are supporting its lead program; delays combined with faster cash use would raise the pressure to find more financing or cut programs.
Nektar Therapeutics earningsNKTR
If Nektar reports progress in its TNFR2 programs, readers can see how a competing approach to the same target as Odyssey's OD-003 is advancing.
Watch for disclosed progress in Nektar's TNFR2 programs. Continued advancement would show another company developing a TNFR2 approach for autoimmune and inflammatory diseases, bringing competition for OD-003 closer; delays would weaken that signal, but would not validate OD-003's aim of increasing the number and function of immune-regulating T cells.
